BR112022021020A2 - Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular - Google Patents
Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celularInfo
- Publication number
- BR112022021020A2 BR112022021020A2 BR112022021020A BR112022021020A BR112022021020A2 BR 112022021020 A2 BR112022021020 A2 BR 112022021020A2 BR 112022021020 A BR112022021020 A BR 112022021020A BR 112022021020 A BR112022021020 A BR 112022021020A BR 112022021020 A2 BR112022021020 A2 BR 112022021020A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapy product
- cell therapy
- patient
- expansion
- manufacturing
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- 230000001413 cellular effect Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
- G06Q10/083—Shipping
- G06Q10/0832—Special goods or special handling procedures, e.g. handling of hazardous or fragile goods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Business, Economics & Management (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Business, Economics & Management (AREA)
- Economics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Human Resources & Organizations (AREA)
- Operations Research (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Tourism & Hospitality (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Development Economics (AREA)
- Entrepreneurship & Innovation (AREA)
Abstract
MÉTODO DE FABRICAÇÃO DE UM PRODUTO DE TERAPIA CELULAR, MÉTODOS DE TRATAMENTO DO PACIENTE COM O PRODUTO DE TERAPIA CELULAR DE EXPANSÃO E FABRICADO, E, MÉTODO DE FABRICAÇÃO DE UM PRODUTO DE TERAPIA CELULAR. Um método para coordenar a fabricação de um produto de terapia celular expandido para um paciente pode incluir receber uma solicitação de pedido celular para expandir o produto de terapia celular para o paciente; gerar um identificador específico do paciente ou identificador de pedido celular associado à solicitação de pedido celular; e iniciar um processo para expandir o produto de terapia celular de pelo menos um pouco de um tumor sólido obtido do paciente. Se os parâmetros de aceitação para o produto de terapia celular de expansão não atenderem a certos critérios de aceitação em um segundo ponto de tempo subsequente a um primeiro ponto de tempo no processo de expansão, determina-se se a repetição da expansão do produto de terapia celular usando a técnica de expansão celular é possível a partir do primeiro ponto de tempo com base nos parâmetros de aceitação no segundo ponto de tempo. Se tal reexecução da expansão for possível, os eventos de tratamento do paciente que usam o produto de terapia celular expandido são reprogramados.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063013942P | 2020-04-22 | 2020-04-22 | |
US202163155711P | 2021-03-02 | 2021-03-02 | |
US202163159806P | 2021-03-11 | 2021-03-11 | |
PCT/US2021/028709 WO2021216920A1 (en) | 2020-04-22 | 2021-04-22 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022021020A2 true BR112022021020A2 (pt) | 2023-02-14 |
Family
ID=76138096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022021020A BR112022021020A2 (pt) | 2020-04-22 | 2021-04-22 | Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular |
Country Status (12)
Country | Link |
---|---|
US (5) | US20210335467A1 (pt) |
EP (1) | EP4139440A1 (pt) |
JP (1) | JP2023524639A (pt) |
KR (1) | KR20230037069A (pt) |
CN (1) | CN115997008A (pt) |
AU (1) | AU2021258257A1 (pt) |
BR (1) | BR112022021020A2 (pt) |
CA (1) | CA3176356A1 (pt) |
IL (1) | IL297442A (pt) |
MX (1) | MX2022013065A (pt) |
TW (1) | TW202206592A (pt) |
WO (1) | WO2021216920A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3532607T3 (da) * | 2016-10-26 | 2024-04-02 | Iovance Biotherapeutics Inc | Restimulation af kryokonserverede, tumorinfiltrerende lymfocytter |
US11024160B2 (en) * | 2016-11-07 | 2021-06-01 | Nio Usa, Inc. | Feedback performance control and tracking |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
WO2023225048A1 (en) * | 2022-05-17 | 2023-11-23 | Synthego Corporation | Systems and methods for engageable platforms and modules for cell processing |
US20240086416A1 (en) * | 2022-09-09 | 2024-03-14 | Honeywell International Inc. | Methods and systems for integrating external systems of records with final report |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7922073B2 (en) * | 1997-10-21 | 2011-04-12 | Carlos De La Huerga | Vial printing method and apparatus |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US20030235908A1 (en) * | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
AU3289202A (en) * | 2000-10-24 | 2002-05-21 | Oncosis Llp | Method and device for selectively targeting cells within a three -dimensional specimen |
JP2004534721A (ja) | 2000-10-31 | 2004-11-18 | ピーアール ファーマシューティカルズ,インク. | 生理活性分子の向上した送達のための方法及び組成物 |
EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
US6615092B2 (en) * | 2001-03-05 | 2003-09-02 | Dell Products L.P. | Method, system and facility for controlling resource allocation within a manufacturing environment |
US20030175242A1 (en) * | 2001-09-17 | 2003-09-18 | Micheal Gruenberg | Cell therapy system |
DE10161064A1 (de) | 2001-12-12 | 2003-07-03 | Siemens Ag | System und Verfahren zur Kommunikation zwischen Softwareapplikationen, insbesondere MES-Applikationen |
US20030149608A1 (en) | 2002-02-06 | 2003-08-07 | Kall Jonathan J. | Suite of configurable supply chain infrastructure modules for deploying collaborative e-manufacturing solutions |
EP1495108A2 (en) * | 2002-04-08 | 2005-01-12 | Millenium Biologix Inc. | Automated tissue engineering system |
EP1503794B9 (en) | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
US9565275B2 (en) | 2012-02-09 | 2017-02-07 | Rockwell Automation Technologies, Inc. | Transformation of industrial data into useful cloud information |
US7076312B2 (en) | 2002-08-02 | 2006-07-11 | Fisher-Rosemount Systems, Inc. | Integrated electronic signatures for approval of process control and safety system software objects |
AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
US7962361B2 (en) | 2002-11-07 | 2011-06-14 | Novitaz | Customer relationship management system for physical locations |
WO2004081021A2 (en) | 2003-03-12 | 2004-09-23 | Duke University | Oligonucleotide mimetics |
CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
KR100845354B1 (ko) | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항-ctla-4 항체의 용도 |
US7444197B2 (en) * | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7528294B2 (en) | 2004-06-18 | 2009-05-05 | The Regents Of The University Of California | Brassica INDEHISCENT1 sequences |
US8239749B2 (en) | 2004-06-25 | 2012-08-07 | Apple Inc. | Procedurally expressing graphic objects for web pages |
EP1793858A4 (en) | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US20070143165A1 (en) | 2005-08-12 | 2007-06-21 | John Roberts | Customer relationship management system and method |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
JP2008066402A (ja) | 2006-09-05 | 2008-03-21 | Fujifilm Corp | 撮像素子および撮像装置 |
WO2008057729A2 (en) | 2006-10-16 | 2008-05-15 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from mulitple device management systems |
US8041444B2 (en) | 2006-12-22 | 2011-10-18 | Harris Stratex Networks Operating Corporation | Intelligent production station and production method |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20110319415A1 (en) | 2008-08-18 | 2011-12-29 | Universit+e,uml a+ee t zu K+e,uml o+ee ln | Susceptibility to HSP90-Inhibitors |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
PL2881402T3 (pl) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
KR101312053B1 (ko) | 2009-02-25 | 2013-09-25 | (주)리치스톤 | 스크롤 유체기계 |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
WO2012033537A1 (en) * | 2010-09-08 | 2012-03-15 | Nodality, Inc. | Benchmarks for normal cell identification |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
SG181559A1 (en) | 2009-12-08 | 2012-07-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
US9783578B2 (en) | 2010-06-25 | 2017-10-10 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
CA3144697A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
EP2737317A2 (en) | 2011-07-28 | 2014-06-04 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing cancer by characterization of tumor cells associated with pleural or serous fluids |
EP2768939B1 (en) | 2011-10-21 | 2016-08-17 | Cell Medica Limited | Device for the aseptic expansion of cells |
EP2776962A4 (en) | 2011-11-07 | 2015-12-02 | Ingenuity Systems Inc | METHODS AND SYSTEMS FOR IDENTIFICATION OF CAUSAL GENOMIC VARIANTS |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
AU2013239366A1 (en) | 2012-03-29 | 2014-10-16 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the BC loop of human PD1 |
US20140088985A1 (en) | 2012-03-30 | 2014-03-27 | Elizur Corporation | Providing healthcare solutions and workflow management |
ES2655842T3 (es) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR y ROS1 en el cáncer |
JP6386447B2 (ja) | 2012-05-18 | 2018-09-05 | ウィルソン ウォルフ マニュファクチャリング コーポレイションWilson Wolf Manufacturing Corporation | 養子細胞療法のための改良された細胞培養法 |
CA2869674A1 (en) | 2012-06-08 | 2013-12-12 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
WO2013188427A1 (en) | 2012-06-11 | 2013-12-19 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
US20140244351A1 (en) | 2013-02-28 | 2014-08-28 | Single Funnel Pty Ltd | Customer relationship management (crm) systems |
JP6257655B2 (ja) | 2013-03-01 | 2018-01-10 | アメリカ合衆国 | 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法 |
RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2014183078A1 (en) | 2013-05-10 | 2014-11-13 | Foundation Medicine, Inc. | Analysis of genetic variants |
GB2517259A (en) | 2013-06-13 | 2015-02-18 | Navinet Inc | Systems, methods, and environment for identification and processing of medical events |
AU2014302589B2 (en) | 2013-06-24 | 2020-05-14 | Wilson Wolf Manufacturing, LLC | Closed system device and methods for gas permeable cell culture process |
HUP1300432A2 (hu) | 2013-07-10 | 2015-01-28 | Tamas Kardos | Downhill kerékpár szerkezet javított felfüggesztéssel |
MX365218B (es) | 2013-09-06 | 2019-05-27 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores. |
CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
US9678505B2 (en) | 2013-10-14 | 2017-06-13 | Invensys Systems, Inc. | Line management in manufacturing execution system |
CN106659913A (zh) | 2014-03-20 | 2017-05-10 | H.李莫菲特癌症中心研究院 | 用于过继细胞疗法的肿瘤浸润淋巴细胞 |
WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
MX370018B (es) * | 2014-04-25 | 2019-11-28 | Bluebird Bio Inc | Metodos mejorados para la elaboracion de terapias celulares adoptivas. |
BR112016028996A2 (pt) | 2014-06-11 | 2018-01-30 | Polybiocept Ab | composição para expansão de linfócitos; método de preparação de uma população de linfócitos clinicamente relevantes; imunoterapia para tratamento ou prevenção de uma doença infecciosa, uma doença cancerígena, ou uma doença autoimune em um mamífero; composição para uso; kit para uso em imunoterapia, em particular, para tratamento de uma doença cancerígena; linfócito clinicamente relevante obtido por um método; e população de linfócitos clinicamente relevantes obtida por um método |
AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
US10108965B2 (en) | 2015-07-14 | 2018-10-23 | Ujet, Inc. | Customer communication system including service pipeline |
KR20220018627A (ko) | 2016-02-29 | 2022-02-15 | 파운데이션 메디신 인코포레이티드 | 종양 돌연변이 부담을 평가하기 위한 방법 및 시스템 |
WO2017210677A1 (en) | 2016-06-03 | 2017-12-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) |
US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
JP7265989B2 (ja) | 2016-10-25 | 2023-04-27 | ウロゲン ファーマ リミテッド | 体腔の免疫調節治療 |
DK3532607T3 (da) | 2016-10-26 | 2024-04-02 | Iovance Biotherapeutics Inc | Restimulation af kryokonserverede, tumorinfiltrerende lymfocytter |
CN109890406A (zh) | 2016-11-10 | 2019-06-14 | 尼克塔治疗公司 | 肿瘤免疫治疗性治疗方法 |
US11101019B2 (en) | 2016-12-08 | 2021-08-24 | Life Technologies Corporation | Methods for detecting mutation load from a tumor sample |
EP3568162A1 (en) | 2017-01-10 | 2019-11-20 | Nektar Therapeutics | Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods |
JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
WO2018204760A1 (en) | 2017-05-05 | 2018-11-08 | David Weiner | Ctla4 antibodies and vaccine combinations and use of same for immunotherapy |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
TWI757528B (zh) | 2017-08-03 | 2022-03-11 | 美商欣爍克斯公司 | 用於增生及感染性疾病治療之細胞激素結合物 |
SG11202002327PA (en) * | 2017-09-15 | 2020-04-29 | Kite Pharma Inc | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
EP3817819A1 (en) | 2018-07-03 | 2021-05-12 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
BR112021014415A2 (pt) | 2019-02-06 | 2021-09-21 | Synthorx, Inc. | Conjugados de il-2 e métodos de uso dos mesmos |
US11246906B2 (en) | 2019-06-11 | 2022-02-15 | Alkermes Pharma Ireland Limited | Compositions and methods for subcutaneous administration of cancer immunotherapy |
-
2021
- 2021-04-22 CA CA3176356A patent/CA3176356A1/en active Pending
- 2021-04-22 BR BR112022021020A patent/BR112022021020A2/pt unknown
- 2021-04-22 MX MX2022013065A patent/MX2022013065A/es unknown
- 2021-04-22 KR KR1020227040425A patent/KR20230037069A/ko active Search and Examination
- 2021-04-22 TW TW110114589A patent/TW202206592A/zh unknown
- 2021-04-22 WO PCT/US2021/028709 patent/WO2021216920A1/en unknown
- 2021-04-22 AU AU2021258257A patent/AU2021258257A1/en active Pending
- 2021-04-22 IL IL297442A patent/IL297442A/en unknown
- 2021-04-22 CN CN202180044820.9A patent/CN115997008A/zh active Pending
- 2021-04-22 JP JP2022562933A patent/JP2023524639A/ja active Pending
- 2021-04-22 EP EP21728131.0A patent/EP4139440A1/en active Pending
- 2021-04-22 US US17/238,092 patent/US20210335467A1/en active Pending
- 2021-06-24 US US17/357,360 patent/US20210407639A1/en active Pending
- 2021-06-24 US US17/357,393 patent/US20210407640A1/en active Pending
- 2021-11-04 US US17/519,065 patent/US20220059202A1/en active Pending
-
2022
- 2022-01-06 US US17/570,195 patent/US11631483B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW202206592A (zh) | 2022-02-16 |
US20210335467A1 (en) | 2021-10-28 |
EP4139440A1 (en) | 2023-03-01 |
US20220059202A1 (en) | 2022-02-24 |
KR20230037069A (ko) | 2023-03-15 |
US20210407639A1 (en) | 2021-12-30 |
JP2023524639A (ja) | 2023-06-13 |
US20220122707A1 (en) | 2022-04-21 |
CA3176356A1 (en) | 2021-10-28 |
MX2022013065A (es) | 2022-12-08 |
WO2021216920A1 (en) | 2021-10-28 |
US11631483B2 (en) | 2023-04-18 |
IL297442A (en) | 2022-12-01 |
US20210407640A1 (en) | 2021-12-30 |
CN115997008A (zh) | 2023-04-21 |
AU2021258257A1 (en) | 2022-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022021020A2 (pt) | Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular | |
BR0212654A (pt) | Ativação e expansão de células | |
Kazantsev et al. | Novel method for glomus-saving carotid endarterectomy sensu AN Kazantsev: cutting the internal carotid artery on the site from external and common carotid artery | |
BR0214065A (pt) | Método e aparelho para a produção de um enxerto de pele e enxerto produzido dessa maneira | |
EP1335305A3 (en) | Algorithm for dynamic selection of data locking granularity | |
BR112023007922A2 (pt) | Método de geração de linfócitos infiltrantes no tumor, método para expandir uma população de linfócitos infiltrantes no tumor (tils) ou linfócitos infiltrantes na medula (mils) e métodos de tratamento de câncer em um sujeito | |
BR112018075443A2 (pt) | processo para a fabricação de uma peça de superliga monocristalina à base de níquel contendo háfnio | |
Bentzen | From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities | |
WO2002077751A3 (en) | Apparatus and method for designing proteins and protein libraries | |
Bittman et al. | Optimal testing of multiple hypotheses with common effect direction | |
AR121916A1 (es) | Sistemas y métodos para coordinar la manufactura de células para inmunoterapia paciente específica | |
BR112022024964A2 (pt) | Método de trabalho para projetar o tempo de espessamento, adaptando os aditivos | |
BR0314351A (pt) | Processos para a produção de um produto de hidroformilação para a preparação de um produto de aldeìdo e de hidroformilação para a preparação de um aldeìdo | |
WO2023077015A3 (en) | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | |
BR9915793A (pt) | Mecanismo e método para formação de hidrato desenvolvido e recuperação de eficiência desenvolvida de agente de expansão em processos para expansão de tabaco e outros produtos agrìcolas | |
ATE391113T1 (de) | Verfahren zur herstellung von pentafluorethan | |
Dujardin et al. | Failure of locked centro-medullary nailing in pseudarthrosis of the humeral diaphysis | |
WO2002091287A3 (en) | Determining structures by performing comparisons between molecular replacement results for multiple different biomolecules | |
US10424398B2 (en) | Method for aligning molecules in three dimensions based upon their correspondence to an exemplary template molecule for use in performing 3D QSAR analyses | |
Voth et al. | Deciphering the dynamic codes: Advances in biomolecular modeling and simulation | |
Lv et al. | Evolution, Hotspots and Trend of Global Geothermal Energy Research | |
Romaniak | Identifying the isomorphism of kinematic chains | |
Naghibzadeh et al. | AAAligner: Anchor-based Approach to Fast Genome Sequence Alignment | |
Walker Jr | A Method for Identifying Redactional Passages in Matthew on Functional and Linguistic Grounds | |
Montañola et al. | Pairwise sequence alignment method for distributed shared memory systems |